Vayet Pharma S.A. (production of lyophilizate in full cycle; quality control of solvent (except piston friction force testing), secondary packaging of solvent into a set with the drug; responsible for batch release)
UkraineAll drugs from this manufacturer
-
The drug is intended for the treatment and prevention of bleeding in patients with hemophilia A (congenital deficiency of coagulation factor VIII). It is suitable for adults and children of any age, including infants.
Dosage form: lyophilisate for solution for injection
Active substance Dosage moroctocog alfa 250 IU ATC: B02BD02
-
The drug is used for the treatment and prevention of bleeding in patients with hemophilia A (congenital deficiency of clotting factor VIII). It is suitable for adults and children of any age.
Dosage form: lyophilisate for solution for injection
Active substance Dosage moroctocog alfa 500 IU ATC: B02BD02
-
The drug is used for the treatment and prevention of bleeding in patients with hemophilia A (congenital deficiency of coagulation factor VIII). It is intended for both adults and children of any age.
Dosage form: lyophilisate for solution for injection
Active substance Dosage moroctocog alfa 1000 IU ATC: B02BD02
-
The drug is used for the treatment and prevention of bleeding in patients with hemophilia A (congenital deficiency of clotting factor VIII). It is suitable for adults and children of any age, including infants.
Dosage form: lyophilisate for solution for injection
Active substance Dosage moroctocog alfa 2000 IU ATC: B02BD02